HopeStage
Back to all studies
CompletedNCT00997984

Morning or evening guanfacine for children with ADHD

About this titleRead the official source — NCT00997984
Medication studyAges 6–12United States + Canada
The study in practice

Understand this study

Who was this study for?

Listed age limits: 6 years to 12 years.

Listed locations
Little Rock and 45 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: November 17, 2009
Recruitment status
Completed
Enrollment listed in the registry
340
Sponsor
Shire
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, Canada
Age range
From 6 Years to 12 Years
Official registry ID
NCT00997984
Official title
Show the full official title

A Phase 3, Double-blind, Randomized, Multicenter, Placebo-controlled, Dose Optimization Study Evaluating the Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children Aged 6-12 With a Diagnosis of Attention-Deficit/Hyperactivity Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Little Rock, United States · El Centro, United States · Rolling Hills Estates, United States

42 more locations
  • San Diego, United States
  • Wildomar, United States
  • Bradenton, United States
  • Gainesville, United States
  • Jacksonville, United States
  • Maitland, United States
  • Orlando, United States
  • West Palm Beach, United States
  • Atlanta, United States
  • Marietta, United States
  • Boise, United States
  • Chicago, United States
  • Oak Brook, United States
  • Indianapolis, United States
  • Terre Haute, United States
  • Overland Park, United States
  • Paducah, United States
  • New Orleans, United States
  • Rockville, United States
  • Rochester Hills, United States
  • Saint Charles, United States
  • Las Vegas, United States
  • Toms River, United States
  • Fargo, United States
  • Oklahoma City, United States
  • Philadelphia, United States
  • Pittsburgh, United States
  • Providence, United States
  • Memphis, United States
  • Austin, United States
  • Houston, United States
  • Lake Jackson, United States
  • Lubbock, United States
  • San Antonio, United States
  • Burlington, United States
  • Herndon, United States
  • Richmond, United States
  • Bellevue, United States
  • Vancouver, Canada
  • Toronto, Canada
  • Whitby, Canada
  • Saskatoon, Canada

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Shire.

Did this study involve medication?

Yes. The study involved medication, including extended-release guanfacine hydrochloride (SPD503), placebo and extended-release guanfacine hydrochloride.

Who was this study for?

Listed age limits: 6 years to 12 years.

Want to explore more studies?

Explore studies